ClinicalTrials.govpublic full text
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
solid tumor, clear cell renal cell carcinoma, tnbc - triple-negative breast cancer, colorectal cancer, crc, rcc, ccrcc, tumor metabolism, glutaminase inhibitor, cb-839, telaglenastat, talazoparib
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 904379
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.